These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
108 related articles for article (PubMed ID: 22994087)
1. [Role of matrix metalloproteinase-9 in the pathogenesis of osteoporosis in patients with chronic obstructive pulmonary disease]. Kochetkova EA; Ugaĭ LG; Maĭstrovskaia IuV; Buria KA; Nevzorova VA Ter Arkh; 2012; 84(8):37-40. PubMed ID: 22994087 [TBL] [Abstract][Full Text] [Related]
2. Circulating matrix metalloproteinase-9 and osteoporosis in patients with chronic obstructive pulmonary disease. Bolton CE; Stone MD; Edwards PH; Duckers JM; Evans WD; Shale DJ Chron Respir Dis; 2009; 6(2):81-7. PubMed ID: 19411568 [TBL] [Abstract][Full Text] [Related]
3. [Metalloproteinase-9/tissue inhibitor of metalloproteinase-1 in induced sputum in patients with asthma and chronic obstructive pulmonary disease and their relationship to airway inflammation and airflow limitation]. Xin XF; Zhao M; Li ZL; Song Y; Shi Y Zhonghua Jie He He Hu Xi Za Zhi; 2007 Mar; 30(3):192-6. PubMed ID: 17572998 [TBL] [Abstract][Full Text] [Related]
4. Interrelationship of circulating matrix metalloproteinase-9, TNF-α, and OPG/RANK/RANKL systems in COPD patients with osteoporosis. Zhang PF; Pan L; Luo ZY; Zhao HJ; Cai SX COPD; 2013 Dec; 10(6):650-6. PubMed ID: 23845033 [TBL] [Abstract][Full Text] [Related]
5. [Concentrations of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in serum of patients with chronic obstructive pulmonary disease]. Piesiak P; Brzecka A; Kosacka M; Passowicz-Muszyńska E; Dyła T; Jankowska R Pol Merkur Lekarski; 2011 Nov; 31(185):270-3. PubMed ID: 22299526 [TBL] [Abstract][Full Text] [Related]
6. [Relationships between the expressions of intercellular adhesion molecule-1 and tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-9 in lung tissues of patients with chronic obstructive pulmonary disease]. Kong YJ; Sun WX; Zhang YM; Shi YZ Zhonghua Jie He He Hu Xi Za Zhi; 2008 Feb; 31(2):129-33. PubMed ID: 18683786 [TBL] [Abstract][Full Text] [Related]
7. Pathogenesis of cigarette smoke-induced chronic obstructive pulmonary disease and therapeutic effects of glucocorticoids and N-acetylcysteine in rats. Xu L; Cai BQ; Zhu YJ Chin Med J (Engl); 2004 Nov; 117(11):1611-9. PubMed ID: 15569474 [TBL] [Abstract][Full Text] [Related]
8. [The role of matrix metalloproteinases-9 and tissue inhibitor of metalloproteinaes-1 in chronic obstructive pulmonary disease]. Xu XM; Sun TY; Lin JB; Zhang HS Zhonghua Yi Xue Za Zhi; 2003 Jul; 83(13):1138-41. PubMed ID: 12921631 [TBL] [Abstract][Full Text] [Related]
9. Identification of patients with chronic obstructive pulmonary disease (COPD) by measurement of plasma biomarkers. Shaker SB; von Wachenfeldt KA; Larsson S; Mile I; Persdotter S; Dahlbäck M; Broberg P; Stoel B; Bach KS; Hestad M; Fehniger TE; Dirksen A Clin Respir J; 2008 Jan; 2(1):17-25. PubMed ID: 20298300 [TBL] [Abstract][Full Text] [Related]
10. Enhanced exhalation of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with COPD exacerbation: a prospective study. Kwiatkowska S; Noweta K; Zieba M; Nowak D; Bialasiewicz P Respiration; 2012; 84(3):231-41. PubMed ID: 22832426 [TBL] [Abstract][Full Text] [Related]
11. [Osteoprotegerin and bone mineral density in patients with chronic obstructive pulmonary disease]. Kochetkova EA; Nevzorova VA; Maĭstrovskaia IuV; Massard G Ter Arkh; 2010; 82(8):10-4. PubMed ID: 20873238 [TBL] [Abstract][Full Text] [Related]
12. [Relationships between circulating matrix metalloproteinase-1, -2 and metalloproteinase-1 levels and bone biochemical markers and bone mineral density in Chinese postmenopausal women]. Guo LJ; Luo XH; Wu XP; Xie H; Zhou HD; Zhang H; Cao XZ; Liao EY Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(11):734-7. PubMed ID: 15949377 [TBL] [Abstract][Full Text] [Related]
14. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Higashimoto Y; Yamagata Y; Iwata T; Okada M; Ishiguchi T; Sato H; Masuda M; Itoh H Eur Respir J; 2005 May; 25(5):885-90. PubMed ID: 15863647 [TBL] [Abstract][Full Text] [Related]
15. [Effects of shuxuening injection on the levels of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in acute exacerbated chronic obstructive pulmonary disease patients]. Wang TJ; Xie ZH; Zhao ZZ Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Feb; 32(2):191-4. PubMed ID: 22574591 [TBL] [Abstract][Full Text] [Related]
16. MMP-9 protein level does not reflect overall MMP activity in the airways of patients with COPD. Lowrey GE; Henderson N; Blakey JD; Corne JM; Johnson SR Respir Med; 2008 Jun; 102(6):845-51. PubMed ID: 18328682 [TBL] [Abstract][Full Text] [Related]
17. [MMP-9 and TIMP-1 levels in the sputum of patients with chronic obstructive pulmonary disease and asthma]. Calikoğlu M; Unlü A; Tamer L; Ozgür E Tuberk Toraks; 2006; 54(2):114-21. PubMed ID: 16924566 [TBL] [Abstract][Full Text] [Related]
18. Circulatory osteoprotegerin is related to osteoporosis of the hip in patients with COPD. Pobeha P; Petrasova D; Tkacova R; Joppa P Respir Med; 2014 Apr; 108(4):621-7. PubMed ID: 24424018 [TBL] [Abstract][Full Text] [Related]
20. Role of Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand in Bone Loss Related to Advanced Chronic Obstructive Pulmonary Disease. Ugay L; Kochetkova E; Nevzorova V; Maistrovskaia Y Chin Med J (Engl); 2016 Jul; 129(14):1696-703. PubMed ID: 27411457 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]